CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.9 USD | +3.25% |
|
+14.10% | +505.44% |
| May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
| May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 224.4 | 51.72 | 42.51 | 264.8 |
| Enterprise Value (EV) 1 | 142.3 | 2.512 | 42.51 | 264.8 |
| P/E ratio | -4.09 x | -2.75 x | -1.12 x | -9.78 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,795 x | 414 x | - | - |
| EV / Revenue | 1,795 x | 414 x | - | - |
| EV / EBITDA | -8,800,286 x | -1,523,695 x | - | - |
| EV / FCF | -9,327,505 x | -1,580,887 x | - | - |
| FCF Yield | -0% | -0% | - | - |
| Price to Book | 3.5 x | 1.08 x | - | - |
| Nbr of stocks (in thousands) | 28,690 | 28,894 | 28,920 | 29,756 |
| Reference price 2 | 7.820 | 1.790 | 1.470 | 8.900 |
| Announcement Date | 3/29/22 | 3/30/23 | 3/28/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net sales 1 | 0.125 | 0.125 | - | - |
| EBITDA | -25.49 | -33.94 | - | - |
| EBIT 1 | -25.73 | -34.72 | -38.39 | -46.9 |
| Operating Margin | -20,580.8% | -27,777.6% | - | - |
| Earnings before Tax (EBT) 1 | -36.12 | -18.79 | -37.94 | -41.6 |
| Net income 1 | -36.12 | -18.79 | -37.94 | -41.6 |
| Net margin | -28,899.2% | -15,035.2% | - | - |
| EPS 2 | -1.910 | -0.6500 | -1.310 | -0.9100 |
| Free Cash Flow | -24.05 | -32.72 | - | - |
| FCF margin | -19,242.4% | -26,172.8% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/29/22 | 3/30/23 | 3/28/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | - | - | - | - |
| EBITDA | -7.562 | -8.821 | -8.566 | -8.676 | -7.88 | - | - | - | - |
| EBIT 1 | -7.74 | -8.986 | -8.753 | -8.881 | -8.101 | -9.633 | -9.579 | -8.861 | -10.32 |
| Operating Margin | -24,967.74% | -28,987.1% | -28,235.48% | -28,648.39% | -26,132.26% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | - | -5.083 | - | -9.614 | -8.435 | -11.1 |
| Net income 1 | 1.596 | -0.874 | -4.149 | -8.688 | -5.083 | - | -9.614 | -8.435 | -11.1 |
| Net margin | 5,148.39% | -2,819.35% | -13,383.87% | -28,025.81% | -16,396.77% | - | - | - | - |
| EPS 2 | 0.5100 | -0.0300 | -0.1400 | -0.3000 | -0.1700 | -0.3000 | -0.3300 | -0.2900 | -0.3800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/29/22 | 5/12/22 | 8/5/22 | 11/10/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | 82.1 | 49.2 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | -24.1 | -32.7 | - | - |
| ROE (net income / shareholders' equity) | -89% | -33.6% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | 2.240 | 1.650 | - | - |
| Cash Flow per Share | -1.180 | -1.090 | - | - |
| Capex | 1.84 | 1.3 | - | - |
| Capex / Sales | 1,468% | 1,037.6% | - | - |
| Announcement Date | 3/29/22 | 3/30/23 | 3/28/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.9
USD
Average target price
11
USD
Spread / Average Target
+23.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +505.44% | 265M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CADL Stock
- Financials Candel Therapeutics, Inc.
